Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. reports commercial and financial developments for a commercial-stage biotechnology business focused on acute care and oncology products. News commonly covers revenue performance and guidance for the Acute Care franchise, including ZYNRELEF and APONVIE, as well as oncology product updates involving CINVANTI and the broader product portfolio.
Company updates also address APONVIE’s role as an FDA-approved IV NK-1 receptor antagonist for prevention of postoperative nausea and vomiting in adults, ZYNRELEF product-handling initiatives for hospital and ambulatory surgical center use, distribution and sales-force activity, intellectual-property matters, and board or governance changes.
Heron Therapeutics (Nasdaq: HRTX) announced on June 29, 2020, that it received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for HTX-011, aimed at managing postoperative pain. The CRL cited the need for additional non-clinical information but did not find any clinical safety or efficacy issues. Heron plans to address these issues and resubmit the application. HTX-011 is a non-opioid analgesic that has shown promise in reducing pain and opioid use in clinical trials.